Topical rapamycin (sirolimus) for facial angiofibromas (Q43246829)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2013

edit

Language	Label	Description	Also known as
English	Topical rapamycin (sirolimus) for facial angiofibromas	scientific article published in January 2013

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

title

Topical rapamycin (sirolimus) for facial angiofibromas (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

main subject

sirolimus

1 reference

based on heuristic

inferred from title

author name string

Bhushan Madke

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

publication date

1 January 2013

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

published in

Indian Dermatology Online Journal

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

volume

4

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

issue

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

page(s)

54-57

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

cites work

The mTOR signalling pathway in human cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

mTOR inhibitors: A novel class of anti-cancer agents

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

An emerging role for TOR signaling in mammalian tissue and stem cell physiology

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

mTOR inhibitors in advanced renal cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Mammalian target of rapamycin: a central node of complex signaling cascades

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Sirolimus for calcineurin inhibitors in organ transplantation: contra

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Stress and mTORture signaling

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

TOR signaling in growth and metabolism

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

25 May 2018

Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

15 August 2018

Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 cases

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

15 August 2018

Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

15 August 2018

Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573457

retrieved

15 August 2018

A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23439391

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23439391

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23439391

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23439391

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23439391

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphangioleiomyomatosis treatment with sirolimus

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23439391

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations]

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23439391

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.4103/2229-5178.105488

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

PMC publication ID

3573457

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

PubMed publication ID

23439391

1 reference

stated in

Europe PubMed Central

PMC publication ID

3573457

retrieved

17 November 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43246829&oldid=1984831777"